Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
东诚药业
002675
Shenzhen Stock Exchange
Company Profile
1. In API business, we have wide competitive advantages in international certification ,international permit ,customers resources, sales network, products structure, and quality management, R&D and reserves. 2. In finished dosage form business, we have the advantage of product reserves. In 2014, we began to establish a professional sales and marketing team and now we have formed a well-established sales and marketing system, including a professional attraction marketing team, an experienced government affairs team, a refined operation marketing team and a responsible sales services team. 3. In R&D, we improve the new product development capabilities through increasing R&D investment, establishing the prefect R&D system, and cooperating with the famous pharmaceutical scientific research institutes actively. 4. We successively have the radiopharmaceuticals production platform (represented by Yunke Pharmaceutical), the radiopharmaceuticals R&D platform (represented by Yitai Pharmaceutical), the radiolabelling and distribution platform -represented by Dongcheng Xinke. The company has become one of the few pharmaceutical enterprises with complete qualification and layout in the key link of radiopharmaceutical industry chains, and the radiopharmaceuticals field has become the new profit growth point of our company.
Full description
Our company continues to implement the development strategy which equally stresses on API and finished dosage forms business, promoting endogenous growth and extensional expansion, realizing sustainable growth with fast pace in biopharmaceutical area. On one hand, we continue to consolidate our foundation in API business, enhancing refined sales and marketing in finished dosage forms business so as to make it becomes our company’s new profit growth point. On the other hand, we actively promote the extensional acquisition work, building our new core competitiveness. In API business, our company specially adjusts main products’ business strategy and performance assessment methods of each system, reinforcing products’ core competitiveness. On the basis of consolidating the current market outcomes, our company is making efforts to develop new customers and new markets. The sales of heparin sodium products has made a breakthrough in Asia and Africa markets and hit the historical peak in domestic market. The sales of heparinoid climbed steadily in Japanese market, exceeding the budget target made in the beginning of the year.In finished dosage forms business: on the one hand, our company continues to use our subsidiary Yantai Dongcheng Beifang Pharmaceuticals Co.,Ltd. as the platform, combining current products including hydrocortisone sodium succinate, menotropins, chorionic gonadotropin, defibrase, urokinase produced in biopharmaceutical industry park and products in development including low molecular weight heparin products and health products, etc, constantly selecting products or enterprises with strategic value in orthopedics, cardiovascular, gynecology & pediatrics and other therapeutic fields, constantly enriching the product line. At the same time, after five years development and running-in, the professional finished dosage forms sales and marketing team has developed into fairly mature finished dosage forms sales and marketing system. Key product -Bai Li Shu(Nadroparin Calcium for Injection) is positioned as the only lyophilization powder and small volume low molecular weight heparin calcium ,which complies with new standard of CFDA. It is far ahead in the sales growth of similar products. Key product ambroxol hydrochloride dispersible tablet, as per CFDA’s new requirement, is firstly launched clinical equivalence evaluation experiment in order to achieve first-mover advantage in future market competition.Nuclear medicine business: Relying on high barrier, good therapeutic effect and powerful sales and marketing capability, Yunke Pharmaceutical will continuously keep rapid growth in next few years. At the same time, company’s budget management, operation management and other aspects have been obviously improved. Scientific projects are steadily promoted, safety and environmental protection are in strictly compliance, quality management is constantly striving for perfection. Related work including land acquisition of the construction of new production line and industrial base’s etc. have been approved by competent Authorities. The business of Dongcheng Xinke, which we newly acquired in 2016, has kept steady development. With the deeper industrial integration and managing input of group company, performance growth of Dongcheng Xinke will gradually improved.